Bioinsider launches COVID-19 virtual meeting series

Bioinsider LLC (Bioinsider), a company dedicated to creating a quality, unbiased virtual meeting platform for communication among the scientific, policymaker, and business communities, has opened registration and a call for speaker proposals for its four-part virtual meeting series, Together as One COVID-19 Series.

COVID-19

Image Credit: Kira_Yan/Shutterstock.com

The series begins Thursday, June 18, 2020 with “Diagnostic Landscape for COVID-19,” which will focus on molecular, serology, rapid testing, and how to properly handle the pandemic with the current testing capacity.

The Together as One COVID-19 Series will provide insights on diagnostics, vaccines, therapeutics, and life after Coronavirus. All net proceeds from the events will go to the World Health Organization’s COVID-19 Solidarity Response Fund.

“Sharing new scientific findings and important perspectives from innovators and decision-makers has never before been so crucial in our industry,” said Bioinsider LLC Founder and CEO Dr. Ngoc ‘Emily’ Le.

With the current state of things, in-person meetings are no longer possible. This is where Bioinsider comes in. Each virtual event will feature presentations from thought leaders, speed networking sessions, and face-to-face breakout brainstorming sessions.

Our objective is to host virtual events that allow attendees and participants to create connections, enrich knowledge, foster collaborations, drive the success of their research, and spark innovations.”

Each meeting in the Together as One COVID-19 Series is available both academic/non-profit and commercial attendees, $25 and $50 respectively. Face-to-face breakout sessions will be limited to 15 participants each and are available for an additional cost of $25.

Members of the scientific and medical communities are encouraged to register early, as speed networking and breakout sessions are available on a first-come-first serve basis. 

Speaker and sponsorship opportunities are also available. For details on submitting a speaker proposal or becoming a sponsor.

About Bioinsider

Founded in 2020, Bioinsider LLC is a group of like-minded individuals dedicated to creating a quality-driven, unbiased virtual meeting platform for communication among the scientific community, policymakers, and business leaders.

The goal of these events is to create connections, enrich knowledge, foster collaborations, drive the success of the research, and spark innovations. For more information.

About Dr. Ngoc ‘Emily’ Le, Founder and CEO, Bioinsider

Dr. Le received her Doctor of Philosophy in Chemistry from the University of Massachusetts, Amherst, and spent years working as a content conference producer and led the product development analytics group at Cambridge Healthtech Institute.

She has nine years of experience working with academics, healthcare, biopharma and executive professionals in technical-scientific and business settings.

She has diverse knowledge in diagnostics, drug development, commercial strategy, and various therapeutic areas, including immuno-oncology, and gene and cell therapies.

Comments

  1. Johnny Le Johnny Le United States says:

    Em tau đó

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
One in four healthy young Marines report long-term physical, cognitive, or psychiatric effects after mild COVID-19